New hope to halt deadly transplant rejection

This study tested whether the drug nintedanib could slow the decline in lung function for people who developed a serious complication called bronchiolitis obliterans syndrome (BOS) after a lung transplant. In this Phase 3 trial, 58 transplant recipients with early to moderate BOS were randomly assigned to receive either nintedanib or a placebo pill for six months. The main goal was to see if the drug could better preserve patients' breathing ability compared to the placebo.